Mode
Text Size
Log in / Sign up
Early Phase 1 N=66 Randomized Single-blind Treatment

Effects of Rocking on Postoperative Ileus Duration Study

Abdominal Cancer

Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Nov 2009
Primary outcome: Primary: Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator. — 3.16; 3.88 Days — p=<0.05

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
Rocking Chair Intervention (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
M.D. Anderson Cancer Center
Primary completion
Feb 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.
3.16; 3.88 <0.05 sig

Summary

Primary Objective: 1. Compare the duration of postoperative ileus (POI) duration (time to first flatus), subjective reports of surgical and gas pain, postoperative pain medication (total milligrams per 24 hours) and postoperative recovery time(length of stay) between two groups of abdominal surgery cancer patients receiving either standard postoperative care or standard care plus the rocking intervention.

Eligibility Criteria

Inclusion Criteria

  • Post abdominal surgical cancer patient, undergoing abdominal surgery
  • Over 21 years of age.
  • Ambulatory.
  • Cognitively intact.
  • Scheduled to have epidural analgesia with fentanyl or dilaudid and/or patient controlled analgesia with morphine or dilaudid as their primary mode of postoperative pain control.

Exclusion Criteria

  • Postoperative abdominal surgical cancer patient less than 21 years of age.
  • Are not ambulatory.
  • Are not cognitively intact.
  • Have any of the following: severe neuromuscular disease, cardiovascular disease, pacemakers, inner-ear disturbances, known peripheral vascular disease that interferes with ambulation, are on sympathetic inhibitory or mood altering drugs. All patients will have epidural and/or patient controlled analgesia as their primary mode of postoperative pain control and those who do not will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00494806). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search